Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Identification of Potentially Therapeutic Immunogenic Peptides From Paracoccidioides lutzii Species

Texto completo
Autor(es):
Silva, Leandro B. R. [1, 2, 3] ; Taira, Cleison L. [1] ; Cleare, Levi G. [2, 3] ; Martins, Michele [4] ; Junqueira, Magno [4] ; Nosanchuk, Joshua D. [2, 3] ; Taborda, Carlos P. [1, 5]
Número total de Autores: 7
Afiliação do(s) autor(es):
[1] Univ Sao Paulo, Dept Microbiol, Inst Ciencias Biomed, Sao Paulo - Brazil
[2] Albert Einstein Coll Med, Dept Med, Div Infect Dis, New York, NY - USA
[3] Albert Einstein Coll Med, Dept Microbiol & Immunol, Div Infect Dis, New York, NY - USA
[4] Fed Univ Rio Janeiro, Dept Biochem, Prote Unit, Inst Chem, Rio De Janeiro - Brazil
[5] Univ Sao Paulo, Inst Med Trop Sao Paulo, Fac Med, Dept Dermatol, Lab Micol Med LIM53, Sao Paulo - Brazil
Número total de Afiliações: 5
Tipo de documento: Artigo Científico
Fonte: FRONTIERS IN IMMUNOLOGY; v. 12, MAY 11 2021.
Citações Web of Science: 0
Resumo

Paracoccidioidomycosis (PCM) is an endemic mycosis in Latin America caused by the thermodimorphic fungi of the genus Paracoccidioides spp. Paracoccidioides lutzii (PL) is one of the 5 species that constitute the Paracoccidioides genus. PL expresses low amounts of glycoprotein (Gp) 43 (PLGp43) and PLGp43 displays few epitopes in common with the P. brasiliensis (PB) immunodominant antigen PBGp43, which is commonly used for serological diagnosis of PCM. This difference in structure between the glycoproteins markedly reduces the efficiency of serological diagnosis in patients infected with PL. We previously demonstrated that peptide 10 (P10) from the PBGp43 induces protective immune responses in in vitro and in vivo models of PB PCM. Since, P10 has proven to be a promising therapeutic to combat PB, we sought to identify peptides in PL that could similarly be applied for the treatment of PCM. PL yeast cell proteins were isolated from PL: dendritic cell co-cultures and subjected to immunoproteomics. This approach identified 18 PL peptides that demonstrated in silico predictions for immunogenicity. Eight of the most promising peptides were synthesized and applied to lymphocytes obtained from peptide-immunized or PL-infected mice as well as to in vitro cultures with peptides or dendritic cells pulsed the peptides. The peptides LBR5, LBR6 and LBR8 efficiently promoted CD4(+) and CD8(+) T cell proliferation and dendritic cells pulsed with LBR1, LBR3, LBR7 or LBR8 stimulated CD4(+) T cell proliferation. We observed increases of IFN-gamma in the supernatants from primed T cells for the conditions with peptides without or with dendritic cells, although IL-2 levels only increased in response to LBR8. These novel immunogenic peptides derived from PL will be employed to develop new peptide vaccine approaches and the proteins from which they are derived can be used to develop new diagnostic assays for PL and possibly other Paracoccidioides spp. These findings identify and characterize new peptides with a promising therapeutic profile for future against this important neglected systemic mycosis. (AU)

Processo FAPESP: 19/20622-2 - Prospecção de novos epítopos antigênicos de isolados de P. lutzii com potencial vacinal
Beneficiário:Leandro Buffoni Roque da Silva
Modalidade de apoio: Bolsas no Exterior - Estágio de Pesquisa - Pós-Doutorado
Processo FAPESP: 18/25171-6 - Prospecção de novos epitopos com potencial vacinal no controle da infecção experimental por Paracoccidioides lutzii
Beneficiário:Leandro Buffoni Roque da Silva
Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado
Processo FAPESP: 16/08730-6 - Patogenicidade fúngica: efeito do tabagismo, resposta imune e a modulação vacinal na paracoccidioidomicose e na histoplasmose
Beneficiário:Carlos Pelleschi Taborda
Modalidade de apoio: Auxílio à Pesquisa - Temático